Paul Gilgen - Koninklijke DSM Head Products
| KDSKFDelisted Stock | USD 25.30 0.00 0.00% |
Insider
Paul Gilgen is Head Products of Koninklijke DSM NV
| Age | 78 |
| Phone | 31 45 578 8111 |
| Web | https://www.dsm.com |
Koninklijke DSM Management Efficiency
The company has return on total asset (ROA) of 0.0402 % which means that it generated a profit of $0.0402 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1189 %, meaning that it generated $0.1189 on every $100 dollars invested by stockholders. Koninklijke DSM's management efficiency ratios could be used to measure how well Koninklijke DSM manages its routine affairs as well as how well it operates its assets and liabilities.Koninklijke DSM NV has accumulated 2.84 B in total debt with debt to equity ratio (D/E) of 0.31, which is about average as compared to similar companies. Koninklijke DSM NV has a current ratio of 2.46, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Koninklijke DSM until it has trouble settling it off, either with new capital or with free cash flow. So, Koninklijke DSM's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Koninklijke DSM NV sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Koninklijke to invest in growth at high rates of return. When we think about Koninklijke DSM's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Christiane Muller | LAir Liquide SA | N/A | |
| Stefan Mosli | Sika AG | 63 | |
| Pierre Bnaich | Givaudan SA | N/A | |
| MarieLaure Roumiguiere | Symrise AG | N/A | |
| Jrme Pelletan | LAir Liquide SA | 53 | |
| HeinzJurgen Bertram | Symrise AG | 65 | |
| Hallvard Bremnes | Givaudan SA | N/A | |
| Yukihito Adachi | Shin Etsu Chemical Co | N/A | |
| MSc MBA | Sika AG | 68 | |
| Fabien Jaunault | Givaudan SA | N/A | |
| Marcos Vazquez | Sika AG | N/A | |
| Executive MBA | Sika AG | 58 | |
| Patricia Heidtman | Sika AG | 50 | |
| Luz Granizo | Sika AG | N/A | |
| Laurent Pieren | Givaudan SA | N/A | |
| Dominik Slappnig | Sika AG | N/A | |
| Raffaella Marzi | Sika AG | 53 | |
| Yasuhiko Saitoh | Shin Etsu Chemical Co | 68 | |
| Franois Abrial | LAir Liquide SA | 61 | |
| Roberto Ascoli | Symrise AG | N/A | |
| Alain Bourdon | Symrise AG | N/A | |
Management Performance
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0402 |
Koninklijke DSM NV Leadership Team
Elected by the shareholders, the Koninklijke DSM's board of directors comprises two types of representatives: Koninklijke DSM inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Koninklijke. The board's role is to monitor Koninklijke DSM's management team and ensure that shareholders' interests are well served. Koninklijke DSM's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Koninklijke DSM's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jan Wolters, Head Chemicals | ||
| Bruno Mller, Head Products | ||
| Paul Gilgen, Head Products | ||
| Manfred Eggersdorfer, VP Advocacy | ||
| Lieke JongTops, Communications Mang | ||
| Geraldine Matchett, CFO and Member of the Managing Board | ||
| Luca Rosetto, VP Products | ||
| Dimitri Vreeze, Member of the Managing Board | ||
| Dave Huizing, Vice President Investor Relations | ||
| Rob Atsma, Head Nederland |
Koninklijke Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Koninklijke DSM a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0402 | |||
| Profit Margin | 0.11 % | |||
| Operating Margin | 0.10 % | |||
| Current Valuation | 23.38 B | |||
| Shares Outstanding | 172.97 M | |||
| Shares Owned By Insiders | 0.09 % | |||
| Shares Owned By Institutions | 56.99 % | |||
| Price To Earning | 37.75 X | |||
| Price To Book | 2.12 X |
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in Koninklijke Pink Sheet
If you are still planning to invest in Koninklijke DSM NV check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Koninklijke DSM's history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |